Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2293]
News [4647]
Articles [192]
Editorials [8]
Conferences [136]
elearning [14]
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel...
Dr David R. Spigel - Tennessee Oncology, Nashville, USA
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC ( Dr David R. Spigel - Tennessee Oncology, Nashville, USA )
26 Oct 2018
Safety analysis of entrectinib for NTRK fusion tumours
Dr George D. Demetri - Harvard Cancer Center, Boston, USA
Safety analysis of entrectinib for NTRK fusion tumours ( Dr George D. Demetri - Harvard Cancer Center, Boston, USA )
26 Oct 2018
ASCEND-8: safety data of ceritinib with or without food in NSCLC
Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea
ASCEND-8: safety data of ceritinib with or without food in NSCLC ( Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea )
26 Oct 2018
CheckMate142: Checkpoint combination therapy in first-line colorectal cancer
Dr Heinz-Josef J. Lenz - Keck School of Medicine of USC, Los Angeles, USA
CheckMate142: Checkpoint combination therapy in first-line colorectal cancer ( Dr Heinz-Josef J. Lenz - Keck School of Medicine of USC, Los Angeles, USA )
26 Oct 2018
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer
Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer ( Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA )
26 Oct 2018
Lung highlights from ESMO 2018
Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy
Lung highlights from ESMO 2018 ( Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy )
26 Oct 2018
Erlotinib for neoadjuvant treatment of EGFR NSCLC
Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical...
Erlotinib for neoadjuvant treatment of EGFR NSCLC ( Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China )
26 Oct 2018
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in...
Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC ( Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France )
25 Oct 2018
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M...
Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer...
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC ( Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, USA )
25 Oct 2018
Comment on the TRIBE-2 study on first and second-line treatment for metastatic...
Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation...
Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer ( Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy )
25 Oct 2018
Ceritinib and ribociclib in ALK-positive NSCLC
Dr Enriqueta Felip - Vall d'Hebron Institute of Oncology (VHIO), Barcelona...
Ceritinib and ribociclib in ALK-positive NSCLC ( Dr Enriqueta Felip - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
24 Oct 2018
Cemiplimab in patients with hepatocellular carcinoma
Dr Michael J. Pishvaian - Georgetown University, Washington, USA
Cemiplimab in patients with hepatocellular carcinoma ( Dr Michael J. Pishvaian - Georgetown University, Washington, USA )
24 Oct 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation